Evidence map›Paper›PMID 37351624›Full record

ArticleCancer chemotherapy and pharmacology2023

Influence of age on pharmacokinetics of capecitabine and its metabolites in older adults with cancer: a pilot study.

Mohsen Shafiei, Peter Galettis, Philip Beale, Stephanie E Reuter, Jennifer H Martin, Andrew J McLachlan, Prunella Blinman

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Mohsen ShafieiConcord Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia. Mohsen.Shafiei@health.nsw.gov.au.ORCID 0000-0002-6208-2000
Peter GalettisHunter Medical Research Institute, Kookaburra Circuit, New Lambton Heights, NSW, Australia.
Philip BealeConcord Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Stephanie E ReuterUniSA Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
Jennifer H MartinHunter Medical Research Institute, Kookaburra Circuit, New Lambton Heights, NSW, Australia.
Andrew J McLachlanSydney Pharmacy School, University of Sydney, Sydney, NSW, Australia.
Prunella BlinmanConcord Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
The University of Sydney · AUHunter Medical Research Institute · AUUniversity of South Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCapecitabine is an oral chemotherapy prodrug of 5-fluorouracil (5-FU) with unpredictable toxicity, especially in older adults. The aim of this study was to evaluate the pharmacokinetics (PK) of capecitabine and its metabolites in younger adults (< 70 years) and older adults (≥ 70 years) receiving capecitabine for solid cancer.

methodsEligible participants receiving capecitabine had 2 venous samples collected on day 14 of cycle 1 and cycle 2 of their treatment. Capecitabine and metabolite concentrations were determined using liquid chromatography with tandem mass spectrometry. A Bayesian estimation approach was used to generate individual estimates of PK parameters for 5-FU. A linear mixed-effect analysis of variance (ANOVA) model was used to compare dose-normalised log-transformed PK parameters between age groups. Correlations were determined by linear regression and logistic regression analyses.

resultsOf the total 26 participants, 58% were male with a median age of 67 years (range, 37-85) with 54% aged < 70 years and 46% aged ≥ 70 years. Participants aged ≥ 70 years, compared to those aged < 70 years, had a greater 5-FU exposure based on area under the concentration-time curve (AUC) of 17% (90% CI 103-134%; 0.893 vs. 0.762 mg h/L) and 14% increase in maximal concentration, C

conclusion5-FU exposure was significantly increased in older adults compared to younger adults receiving equivalent doses of capecitabine, and is a possible cause for increased toxicity in older adults.

Indexed as

DeoxycytidineNeoplasmsAdultAgedAged, 80 and overArea Under CurveBayes TheoremCapecitabineFemaleFluorouracilHumansMaleMiddle AgedPilot ProjectsCapecitabineDeoxycytidineFluorouracilCancerCapecitabineGeriatric toolsOlder adultsPharmacokineticsToxicity

Identifiers

PMID37351624
OpenAlexW4381714931

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.